Involvement of neurotransmitters in the action of apelin-13 on passive avoidance learning in mice by Telegdy, Gyula et al.
 1 
 
 
Involvement  of neurotransmitters in the action of apelin-13  
on passive avoidance learning in  mice. 
Gyula Telegdy a,b, Agnes Adamikb, Miklós Jászberényia 
Department of Pathophysiologya, Neuroscience Research Group of 
the Hungarian Academy of Sciencesb, University of Szeged, 
Szeged, Hungary 
 
 
Corresponding author: Gyula Telegdy 
                      Dept. Pathophysiology 
                      University of Szeged 
                      Semmelweis 1 
                      6721 Szeged, Hungary 
                       Tel.: 36 62 545797 
                       Fax: 36 62 545710
 2 
 
Abstract 
The  widespread distribution of apelin-13 and apelin receptors 
in the brain suggests an important function of this 
neuropeptide in the  brain that has not been explored 
extensively so far.  In the present work,  apelin-13  was 
found facilitate the consolidation of passive avoidance 
learning in mice.  In  order to assess the possible 
involvement of transmitters in this action, the animals were 
pretreated with the following receptor blockers in  doses 
which themselves  did not influence the behavioral paradigm: 
phenoxybenzamine (a nonselective α-adrenergic receptor 
antagonist), propranolol (a β-adrenergic receptor antagonist), 
cyproheptadine (a nonselective 5-HT2 serotonergic receptor 
antagonist), atropine  (a nonselective muscarinic 
acetylcholine receptor antagonist),  haloperidol, (a D2, D3, 
D4 dopamine receptor antagonist), bicuculline  (a  γ-
aminobutyric acid subunit A (GABA-A) receptor  antagonist),  
naloxone (a nonselective opioid receptor  antagonist), and  
nitro-L-arginine (a nitric oxide synthase inhibitor).  
Phenoxybenzamine, cyproheptadine, atropine, haloperidol, 
bicuculline and nitro-L-arginine prevented the action of 
apelin-13. Propranolol and naloxone were ineffective. The data 
suggest that apelin-13 elicits its action on the consolidation 
of passive avoidance learning via  α-adrenergic, 5-HT2 
serotonergic, cholinergic, dopaminergic, GABA-A-ergic  and 
nitric oxide mediations. 
 
Key words: apelin-13, passive avoidance learning, transmitter 
mediation. 
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1. Introduction 
The first known apelin, apelin-36,  isolated from bovine 
stomach extracts [23],  is the endogenous ligand of an  orphan 
G protein-coupled receptor, APJ, identified in a human gene by 
O’Dowd et al. (1993)[15]. It is derived from a 77-amino-acid 
precursor, preproapelin, identified in human and bovine tissue 
[23], which is processed to the  molecular forms: apelin-36, 
apelin-26, apelin 19, apelin-17, apelin-13, apelin-12 in 
different tissues [9,17].  
Synthetic C-terminal fragments of preproapelin, consisting of 
13 to 19 amino acids, were found to exhibit significantly 
higher activities at the receptors than that of apelin-36 
[9,24]. The   most extensively studied. apelin-13   has been 
shown to participate in the regulation of cardiovascular 
function [11,19], fluid homeostasis [11,22], and the 
pituitary-adrenal axis [8,22].  Apelin receptors and apelin 
are widely distributed in the central nervous system (CNS) 
[3,6,13,18.], suggesting that apelin may be of importance  in 
the regulation of certain CNS functions. We earlier 
demonstrated that apelin-13  increases the open-field 
activity, the plasma corticosterone level and the core 
temperature in male rats [8]. At  present no data are 
available on the action of apelin-13 on learning and memory 
function or on  the possible involvement of neurotransmitters 
in such  action. The aim of the present work was to elucidate 
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the action of apelin-13 administered i.c.v. on passive 
avoidance learning in mice. The possible involvement of 
neurotransmitters in the passive avoidance learning was 
studied by pretreating the animals with certain 
neurotransmitter blockers.  
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 2. Methods and Materials 
2.1. Animals     
    CFLP male mice  weighing 25-28 g, were used. The animals 
were kept and handled during the experiments in accordance with 
the Regulation of the Albert Szent-Györgyi Medical University 
Ethical Committee for the Protection of Animals in Research. 
Five animals per cage were housed in a light- (lights on at 0600 
h and off at 1800 h)  and temperature-controlled room (23 oC)   
and had free access to food and water . 
2.2. Surgery 
    The mice were anesthetized with sodium pentobarbital 
(Nembutal 35 mg/kg i.p.) and a cannula was introduced into the 
lateral cerebroventricle and fixed to the skull with dental 
cement and acrylic resin. The animals were allowed to recover 
for 5 days. The correct location of the cannula was checked by 
dissecting the brain following completion of the experiments. 
Only animals with the correct location of the cannula were used 
in the evaluation of the experiments. All experiments were 
performed in the morning period.  
 
2.3. Materials 
Different doses of apelin-13 (Bachem, Bubendorf, Switzerland) 
dissolved in saline, or saline alone (control animals), in a 
volume of 2 µl, were injected i.c.v. into conscious rats. 
Apelin-13 in a quantity of 10 µg per ampoule was lyophilized 
and stored at −20 °C. Immediately before the experiments  
apelin-13 was dissolved in sterile pyrogen-free 0.9% saline 
and administered i.c.v.  in a volume of 2 µl via a cannula. 
 
2.4. Treatments 
    
  For the  administration of the apelin-13 (Bachem, Bubendorf, 
Switzerland)  a stainless steel cannula with an external 
diameter of 0.7 mm was  implanted stereotaxically into the right 
lateral brain ventricle. The peptides were injected icv via the 
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cannula  in a volume of  2 µl.  For the transmitter interaction 
the most effective dose of apelin-13 (2 µg)  was selected. 
    The  antagonists of  neurotransmitters was given 
intraperitoneally the Nitro-L-arginine was given icv. Following 
receptor blockers were used: Phenoxybenzamine hydrochloride was 
obtained from Smith Kline & French (Herts, UK);  
propranolol hydrochloride  from ICI Ltd. (Macclesfield, UK); 
cyproheptadine hydrochloride  from Tocris (Bristol, UK); 
atropine sulphate  from EGYS (Budapest, Hungary); haloperidol  
from G. Richter (Budapest, Hungary); and bicuculline 
methiodide  from Sandoz (Basle, Switzerland); naloxone 
hydrochloride (Endo Labs, Wilmington USA). Nitroω-L-Arginine 
methylester hydrochloride (Sigma St Louis USA). 
 
2.5. Behavioural testing 
 
2.5.1. Passive avoidance test  
   
    One-trial learning, step-through passive avoidance behavior 
was measured according to Ader et al. [2]. Briefly, mice were 
placed on an illuminated platform and allowed to enter a dark 
compartment. Since mice prefer dark to light, they normally 
entered within 5 s. Two additional trials were delivered on the 
following day. After the second trial, unavoidable mild electric 
footshocks (0.75 mA, 2 s) were delivered through the grid floor. 
Having entered the box, the animals could not escape the 
footshock. After this single trial, the mice were immediately 
removed from the apparatus and were treated. The consolidation 
of passive avoidance behavior was tested 24 h later. For 
consolidation, the animals were treated icv with Apelin-13, 1.0  
and 2.0 ug. For further test the  2 µg   was selected. The 
receptor blocker  was given following the learning trial  and 
3o min later,  the Apelin-13 (2 µg). In the 24 h testing each 
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animal was placed on the platform and the latency to enter the 
dark compartment was measured up to a maximum of  300 s.  
2.6. Statistical analysis 
    The analysis of variance (ANOVA) test was followed by 
Tukey’s test for multiple comparisons with unequal cell size. 
Probability values (P) of less than 0.05 are considered 
significant. 
3. Results 
     Apelin-13 in a dose of 1 µg/2 µl  i.c.v. had no action on 
the consolidation of passive avoidance learning, while 2 µg 
i.c.v. significantly facilitated the consolidation of passive 
avoidance memory [F(2,30)=16.70]; p<0.05 (Fig. 1).   
      In the phenoxybenzamine-pretreated group, apelin-13 (2 
µg/2 µl i.c.v.) facilitated the consolidation of passive 
avoidance learning [F(3,18)=12.70]; p<0.05.  Phenoxybenzamine 
(2 mg/kg i.p.) itself had no action, but fully blocked the 
action of apelin-13 (Fig. 2). 
     In the cyproheptadine-pretreated group, apelin-13 (2 µg/2 
µl i.c.v.) facilitated the consolidation of passive avoidance 
learning  [F(3,18)=10.55]; p<0.05. Cyproheptadine  
(l mg/kg i.p.) itself had no action, but fully blocked the 
action of apelin-13 (Fig. 3). 
     In the atropine-pretreated group, apelin-13 (2 µg/2 µl 
i.c.v.) facilitated the consolidation of passive avoidance 
learning [F(3,19)=8.96];p<0.05. Atropine (2 mg/kg i.p.) itself 
had no action, but fully blocked the action of apelin-13 (Fig. 
4). 
     In the haloperidol-pretreated group, apelin-13 (2 µg/2 µl 
i.c.v.) facilitated the consolidation of passive avoidance 
learning [F(3,19)=5.12];p<0,05. Haloperidol (10 µg/kg i.p.) 
itself had no  action, but fully blocked the action of apelin-
13 (Fig. 5). 
     In the bicuculline-pretreated group, apelin-13 (2 µg/2 µl 
i.c.v.) facilitated the consolidation of passive avoidance 
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learning. [F(3,19)=12.76] ; p<0.05. Bicuculline (1 mg/kg i.p.) 
itself had no action, but fully blocked the action of apelin-
13 (Fig. 6). 
     In the nitro-L-arginine- pretreated group, apelin-13 (2 
µg/2 µl i.c.v.) facilitated the consolidation of passive 
avoidance learning [F(3,18=9,21)] ; p<0.05. Nitro-L-arginine 
(10  µg/2 µl i.c.v) itself had no action, but  blocked the 
action of apelin-13 (Fig.7). 
     The propranolol and naloxone-pretreatment had no action 
on apelin-13-induced facilitation of the consolidation of 
passive avoidance learning ( data are not shown). 
 
4. Discussion 
 
      The wide-ranging  distribution of apelin and apelin 
fibers both  in the CNS and in the periphery suggested  the 
important functions of apelin  in physiological processes 
[3,6,13,18]. 
      Apelin-13 has been found  to increase the water intake 
[11,22] and to decrease  the blood pressure [11,19],  the 
latter in  a  nitric oxide-dependent manner [24].  
Additionally it either increases [30], or reduces the food 
intake, depending on  the mode of  application of apelin-13 
[20]. Its enhancement of the adrenal function [8,22],  
involves the participation  of  CRH [8,12] and vasopressin 
[12]. 
     Apelin-13  causes a body temperature elevation [8,30], 
which seems to be prostaglandin-dependent [8].  Apelin-13 
increases locomotion [30] and rearing in an open-field. 
Haloperidol, a  dopamine receptor blocker, diminishes the 
action of apelin-13 [8]. Less is known about the direct action 
of apelin-13 on the central nervous system. 
Apelin has been  shown to exert neuroprotective action  in  a 
number of experimental conditions [5], in  cultures it  
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markedly prevents   apoptosis in mouse cortical neurons [31] 
and it  protects hippocampal neurons against  NMDA 
excitotoxity [14]. 
    No data are available  as yet  regarding the action on 
learning and memory functions. The present work  demonstrates 
that apelin-13 administered  i.c.v. improves learning and 
memory consolidation in passive avoidance learning. Since  
learning and memory function are rather complicated processes, 
involving not only learning, but intention, fear, emotion, 
motivation, locomotion, etc. it is not surprising that a 
number of transmitter  mediations are involved in these 
processes. A  cholinergic mechanism seems to be one of the 
important means of  transmission of the action of certain 
neuropeptides in memory consolidation processes. Our earlier  
work  demonstrated that practically all of the neuropeptides 
which improved the memory in a passive avoidance paradigm, 
involved this form of transmission.( e.g. Telegdy, G. 1984. 
[25]. Alpha-adrenergic, serotonergic, dopaminergic and  GABA-
A-ergic mechanisms seems to be important. It would be 
interesting to establish, which transmitters are involved in 
certain components of a learning processes, which will lead to  
a memory consolidation. It seems that nitric oxide is involved 
not only in the learning process [27]  but also  in the blood 
pressure-lowering action of apelin-13 [24].  
    Naloxone and propranolol were ineffective in the doses 
used in these experiments, however the same dose of naloxone 
could block the action of growth hormone-releasing hormone 
antagonist in a similar  test [28], furthermore propranolol  
attenuated the action  orexin A and urocortin in the passive 
avoidance test [26, 29] and fully blocked the  pituitary 
adenylate cyclase activating polypeptide action in the open-
field activity [1]. 
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      Most of the evidence suggests that apelin-13  is mainly 
a neuromodulator, acting via certain transmitters eliciting a 
given action. 
      Finally, in view of the multiple actions of apelin-13  
in physiological and pathophysiological processes, which are 
not reviewed in  detail in this paper, we fully   agree with 
other authors [4,7,10,21]  that apelin-13  and its analogues 
or antagonists  could be  targets for the development  of 
drugs influencing  pathological processes and are   well worth  
further exploration. 
 
5. Conclusion 
The data presented demonstrate that apelin-13, administered 
i.c.v., facilitates the memory consolidation  in  a passive 
avoidance paradigm via number of transmitter mediation, acting  
as a neuromodulator. 
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Highlight 
Apelin-13 has been tested on passive avoidance learning 
following i.c.v administration in  mice.  
Apelin-13 facilitates the memory consolidation. 
In the memory consolidation, the following transmitters are 
involved: alpha-adrenergic, serotonergic, cholinergic, 
dopaminergic, GABA-A-ergic and nitric oxide. 
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Fig.1 
 
Fig.1.The action  of different doses of apelin-13 administered i.c.v. immediatelly following 
the learning trial, on the consolidation of passive avoidance response. Data are expressed as 
means ± S.E.M. Number in  bars are the numbers of animals used. 
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Fig.2. 
 
Fig.2. The effect of a nonselective α–adrenergic receptor antagonist, phenoxybenzamine (2 
mg/kg i.p) on apelin-induced (2 µg/2 µl i,c.v)  consolidation  of passive avoidance learning. . 
Data are expressed as means ± S.E.M. Number in  bars are the numbers of animals used. 
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Fig.3. 
 
Fig. 3. The effect of a nonselective 5-HT2 receptor antagonist, cyproheptadine (1 mg/kg i.p) 
on apelin-induced (2 µg/2 µl i.c.v) consolidation  of passive avoidance learning. . Data are 
expressed as means ± S.E.M. Number in  bars are the numbers of animals used. 
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Fig. 4. 
 
Fig.4. The effect of a nonselective muscarinic acethylcholine receptor antagonist, atropine (2 
mg/kg i.p) on apelin-induced (2 µg/2 µl i.c.v) consolidation  of  passive avoidance learning. . 
Data are expressed as means ± S.E.M. Number in  bars are the numbers of animals used. 
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Fig.5. 
 
 
Fig.5 . The effect of a D2,D3,D4 dopamine receptor antagonist, haloperidol 10 µg/kg i.p) on 
apelin-induced (2 µg/2 µl i.c.v) consolidation  of passive avoidance learning. . Data are 
expressed as means ± S.E.M. Number in  bars are the numbers of animals used. 
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Fig.6. 
 
Fig.6. The effect of a γ-aminobutyric acid subunit A (GABA-A) receptor antagonist 
bicuculline (1 mg/kg i.p), on apelin-induced (2 µg/2 µl i.c.v) consolidation  of passive 
avoidance learning. . Data are expressed as means ± S.E.M. Number in  bars are the numbers 
of animals used. 
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Fig.7. 
 
Fig.7. The effect of a  nitric oxide (NO) synthase inhibitor, nitro-L-arginine (10 µg/ 2µl) on 
apelin-induced(2 µg/2 µl i.c.v)  consolidation  of passive avoidance learning. Data are 
expressed as means ± S.E.M. Number in  bars are the numbers of animals used. 
 
 25 
  
 
